C. difficile Papers

Latest from the Clostridium difficile research community. Edited by @nataszahain

[C. difficile Papers @Cdiff_Papers]

@WCmicrobiome

[Microbiology Spectrum @JournalSpectrum]

A new antimicrobial peptide designed based on Clostridioides difficile IF1 shows broad-spectrum inhibitory activities against C. difficile and other bacterial strains. https://t.co/7kIGgaGKXp

[IDSA @IDSAInfo]

In @CIDJournal, Pablo Okhuysen, MD, FACP, FIDSA, and colleagues aim to confirm the superiority of ridinilazole over vancomycin on Sustained Clinical Response and recurrent CDI as reported in a Phase II Study.

Read: https://t.co/TM6jlH0gkG

[The Garey Lab @TheGareyLab]

Friday Celebrations! Chenlin Hu, PhD and @GareyKgarey published a review of microscopy methods for C. difficile in Anaerobe! 🔬🦠
Check it out ⬇️⬇️
https://t.co/xlUi9ljaXX
@AnaerobeSociety @UH_Pharmacy

[The Garey Lab @TheGareyLab]

🌟And the publications keep coming!🌟
Check out our labs most recent work on ibezapolstat activity against MDR C. difficile strains ⬇️⬇️
https://t.co/v47gdM43cc

TLDR: IBZ bactericidal activity was similar to the MIC and maintained in wild-type and non-susceptible strains.

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🆕️🔥Multicenter cohort study included adults with C. difficile infection @CIDJournal
Vancomycin MIC >2 μg/mL in Clostridioides difficile was associated with decreased odds of 30-day sustained clinical response & lower 14-day initial cure rates #IDXposts https://t.co/ZEgizivUhz

[Microbiome Science @MbiomeScience]

It's not just about age anymore. #Clostridioidesdifficile infection is reaching beyond traditional risk groups. #guthealth #Cdiff

[Simplify Rx 📱 @simplify_drugs]

Clindamycin attacking the normal flora 🥊 https://t.co/d4RKzy5eBB

[Charles M. Dozois @Dozois_CM]

Pleased to share this publication on vaccine potential of Salmonella against C. difficile in a mouse model: a collaboration with Brian Ward and Ph. D. student Kaitlin Winter @MIMM_McGill and my group @inrsciences @infectiopole. Out in Microbiol. Spectrum: https://t.co/Ccz1OWU2fT

[GutMicrobiota Health @GMFHx]

Have you seen this new @AmCollegeGastro monograph on microbiome therapeutics?

✅ Essential aspects of methods for analyzing the microbiome
✅ Present and future therapeutics for C. difficile
✅ Non-prescription therapeutics

👉 https://t.co/LGKNgsPW1C

[Icahn School of Medicine at Mount Sinai @IcahnMountSinai]

New findings shed light on the key #microbes that protect against recurrent #Clostridiodes difficile infection and #MultipleSclerosis, pointing to future treatment opportunities with live #biotherapeutics. Read more: https://t.co/Tcm4WuQe97

#Immunology

[Beth Stadtmueller @StadtmuellerLab]

Happy to share the latest preprint from the @StadtmuellerLab - an incredible effort by recent PhD student @Sonya31397350! Engineered Secretory Immunoglobulin A provides insights on antibody-based effector mechanisms targeting Clostridiodes difficile https://t.co/oRKW4aeKPe

[C. difficile Papers @Cdiff_Papers]

Fecal Microbiota Transplantation: Information for the Pediatrician
https://t.co/TkXfPQrmLF

[C. difficile Papers @Cdiff_Papers]

Genetic variation in the human leukocyte antigen region confers susceptibility to Clostridioides difficile infection

https://t.co/31f0JTxfzV

[C. difficile Papers @Cdiff_Papers]

Update on Microbiota-derived therapies for recurrent Clostridioides difficile infections, 2023
https://t.co/VylWygEfJ2

[Patient Worthy @PatientWorthy]

C. Diff: Professors Suggest Inflammation, Not Bacteria Should be Targeted https://t.co/qPlA0HYWQm #CDiff #ClostridioidesDifficile

[Ed Kuijper @EdKuijper2]

Grat to Jannie and CMAT for this study on bacterial and fungal microbiome interactions in patients colonized or infected with Cdiff. @EurFmt
@CMIJournal @SmitsLab
https://t.co/8d2aCbjaeZ

[Biomedical Journal @BiomedJ]

The role of gut fungi in #Clostridioides difficile infection

https://t.co/eJ8bQdRTJ6 #OpenAccess #mycology #Cdiff

[Silvio Ragozzino is on 🦋 @RagozzinoSilvio]

🆕🔥Our study on C. difficile infections among allogeneic HCT recipients in the framework of the Swiss Transplant Cohort Study🇨🇭@BMTjournal @TheEBMT
A short summary 🔽1/5 #IDTwitter https://t.co/fknqY0NNGs

[C. difficile Papers @Cdiff_Papers]

Doxycycline tied to lower risk for C. difficile in pneumonia patients

https://t.co/6XAnpH9BRF